source
- Inhibrx reports promising mid-stage data for OX40 agonist and plans vaccine combos early next yearInhibrx Biosciences announced that its OX40 agonist showed encouraging activity in a mid-stage trial involving immunogenic cancers. The data suggest the agent may also enhance responses when paire…
- BrainChild Bio raises $116 million to fund pivotal pediatric brain tumor CAR-T trialBrainChild Bio, a Seattle-based biotech, announced it has secured $116 million in financing to support a pivotal clinical trial of its CAR-T therapy aimed at pediatric brain tumors. The funding ro…